Foster Paul A 4
4 · Xencor Inc · Filed Aug 16, 2018
Insider Transaction Report
Form 4
Xencor IncXNCR
Foster Paul A
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2018-08-14$11.05/sh+15,496$171,231→ 20,448 total - Exercise/Conversion
Stock Option (right to buy)
2018-08-15−106→ 74,398 totalExercise: $11.05Exp: 2024-02-20→ Common Stock (106 underlying) - Sale
Common Stock
2018-08-15$41.10/sh−106$4,357→ 4,952 total - Exercise/Conversion
Stock Option (right to buy)
2018-08-14−15,496→ 74,504 totalExercise: $11.05Exp: 2024-02-20→ Common Stock (15,496 underlying) - Sale
Common Stock
2018-08-14$41.11/sh−15,496$636,980→ 4,952 total - Exercise/Conversion
Common Stock
2018-08-15$11.05/sh+106$1,171→ 5,058 total - Sale
Common Stock
2018-08-16$41.10/sh−20,739$852,373→ 4,952 total - Exercise/Conversion
Common Stock
2018-08-16$11.05/sh+20,739$229,166→ 25,691 total - Exercise/Conversion
Stock Option (right to buy)
2018-08-16−20,739→ 53,659 totalExercise: $11.05Exp: 2024-02-20→ Common Stock (20,739 underlying)
Footnotes (3)
- [F1]Includes the following shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan: 1,207 shares of Common Stock acquired on June 10, 2015, 1,212 shares of Common Stock acquired on December 10, 2015 and 114 shares of Common Stock acquired on June 9, 2018.
- [F2]The weighted average sale price for the transaction reported was $41.1061, and the range of prices were between $41.10 and $41.120. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- [F3]The stock option is fully vested.